Moleculin Biotech (NASDAQ:MBRX) Share Price Crosses Below Fifty Day Moving Average – Time to Sell?

Moleculin Biotech, Inc. (NASDAQ:MBRX) shares passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.14 and traded as low as $0.41. Moleculin Biotech shares last traded at $0.4450, with a volume of 991,840 shares.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MBRX. Wall Street Zen downgraded Moleculin Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $22.00.

Moleculin Biotech Stock Performance

The firm’s 50 day simple moving average is $2.14 and its 200-day simple moving average is $2.57. The company has a market capitalization of $3.16 million, a price-to-earnings ratio of -0.02 and a beta of 1.83.

Moleculin Biotech (NASDAQ:MBRX) last issued its earnings results on Thursday, May 14th. The company reported ($3.54) EPS for the quarter, missing the consensus estimate of ($2.33) by ($1.21). As a group, equities analysts anticipate that Moleculin Biotech, Inc. will post -3.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech at the end of the most recent reporting period. Institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.